Pharmacotherapy of erectile dysfunction: Focus on cardiovascular safety

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 531-540

  Reffelmann, Thorsten ^a   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Erectile dysfunction; Hypotension; Nitrate; Phophodiesterase 5 (PDE5); Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; MILRINONE; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; TESTOSTERONE; TICLOPIDINE; VARDENAFIL; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; ARTERY DILATATION; ARTERY MUSCLE; BLEEDING DISORDER; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSENSUS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORPUS CAVERNOSUM; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; EPISTAXIS; ERECTILE DYSFUNCTION; EYE DISEASE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOTENSION; LIVER TOXICITY; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SINUS ARRHYTHMIA; STOMACH HEMORRHAGE; STOMACH VARICES; SYNCOPE; VAGUS TONE;

ADMINISTRATION, ORAL; APOMORPHINE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOPAMINE AGONISTS; DRUG INTERACTIONS; HUMANS; HYPOTENSION; IMPOTENCE; MALE; NITRIC OXIDE DONORS; PATIENT SELECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RISK ASSESSMENT;

EID: 19444370014     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.531     Document Type: Review

References (87)

1. JOHANNES CB, ARAUJO AB, FELDMAN HA et al.: Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J. Urol. (2000) 163:460-463.
2. FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. (1994) 151:54-61.
3. VIRAQ R, BOUILLO P, FRYDMAN D: Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet (1985) 1:181-184.
4. O'KANE PD, JACKSON G: Erectile dysfunction: is there silent obstructive coronary artery disease? Int. J. Clin. Pract. (2001) 55:219-220.
5. CHEITLIN MD, HUTTERAM, KENNEDY JW et al.: Use of sildenafil (Viagra) in patients with cardiovascular disease. J. Am. Coll. Cardiol. (1999) 33:273-282.
6. GOLDSTEIN I, LUE TF, PADMA-NATHAN H et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. (1998) 338:1397-1404.
7. MORALES A, GINGELL C, COLLINS M et al.: Clinical safety of oral Sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int. J. Impot. Res. (1998) 10:69-73.
8. BROCK GB, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. (2002) 168:1332-1336.
9. NAGAO K, ISHII N, KAMIDONO S et al.: Safety and efficacy of vardenafil in patients with erectile dysfunction: results of a bridging study in Japan. Int. J. Urol. (2004) 11:515-524.
10. LEVINE LA: Diagnosis and treatment of erectile dysfunction. Am. J. Med. (2000) 109:3S-12S.
11. NURNBERG HG, HENSLEY PL, GELENBERG AJ et al.: Treatment of antidepressant-associated sexual dysfunction with Sildenafil: a randomized controlled trial. JAMA (2003) 289:56-64.
12. MONTORSI F: Tolerability and safety of apomorphine SL (Ixense). Int. J. Impot. Res. (2003) 25:S7-S9.
13. FEENSTRA J, VAN DRIE-PIERIK RJ, LACLE CF et al.: Acute myocardial infarction associated with sildenafil. Lancet (1998) 352:957-958.
14. ZUSMAN RM, MORALES A, GLASER DB et al.: Overall cardiovascular profile of sildenafil citrate. Am. J. Cardiol. (1999) 83:35C-44C.
15. KLONER RA: Cardiovascular risk and Sildenafil. Am. J. Cardiol. (2000) 86:57F-61F.
16. WYSOWSKI DK, FARINAS E, SWARTZ L: Comparison of reported and expected deaths in: sildenafil (Viagra) users. Am. J. Cardiol. (2002) 89:1331-1334.
17. REFFELMANN T, KLONER RA: Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc. Res. (2003) 59:441-449.
18. DEBUSK R, DRORY Y, GOLDSTEIN I et al.: Management of sexual dysfunction in patient with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am. J. Cardiol. (2000) 86:175-181.
19. MICHELAKIS E, TYMCHAK W, LIEN D et al.: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 105:2398-2403.
20. WILKENS H, GUTH A, KÖNIG J et al.: Effect of inhaled iloprost plus oral Sildenafil in patients with primary pulmonary hypertension. Circulation (2001) 104:1218-1222.
21. GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 44:1488-1496.
22. REFFELMANN T, KLONER RA: Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation (2003) 108:239-244.
23. KUGIYAMA K, YASUE H, OKUMURA K et al.: Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation (1996) 94:266-271,
24. KATZ SD, BALIDEMAJ K, HOMMA S et al.: Acute Type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. (2000) 36:845-851.
25. BEAVO JA: Cyclic nucleoside phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. (1995) 75:725-748.
26. WALLIS RM, CORBIN JD, FRANCIS SH et al.: Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83:3C-12C.
27. GRESSER U, GLEITER CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitor Sildenafil, vardenafil and tadalafil: review of the literature. Eur. J. Med. Res. (2002) 7:435-446.
28. WEBB DJ, FREESTONE S, ALLEN MJ et al.: Sildenafil citrate and blood-pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium channel antagonist. Am. J. Cardiol. (1999) 83:21C-28C.
29. NICHOLS DJ, MUIRHEAD GJ, HARNESS JA et al.: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol. (2002) 53:5S-12S.
30. KLONER RA, MOHAN P, NORENBERG C et al.: Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction: an analysis of five placebo-controlled trials. Pharmacol. Ther. (2002) 22:1371-1376.
31. CORBIN JD: Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. (2002) 56:453-459.
32. BROCK H, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. (2002) 168:1332-1336.
33. EMMICK JT, STUEWE SR, MITCHELL M: Overview of the cardiovascular effects of tadalafil. Eur. Heart J. (2002) 4:H32-H47.
34. KLONER RA, HUTTER AH. EMMICK JT et al.: Time course of the interaction between tadalafil and nitrates. J. Am. Coll. Cardiol. (2003) 42:1855-1860.
35. VARDI Y, KLEIN L, NASSAR S et al.: Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology (2002) 59:747-752.
36. KLONER RA, BROWN M, PRISANT LM et al.: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am. J. Hypertens. (2001) 14:70-73.
37. NAGAO K, ISHII N, KAMIDONO S et al.: Safety and efficacy of vardenafil in patients with erectile dysfunction: results of a bridging study in Japan. Int. J. Urol. (2004) 11:515-524.
38. KLONER RA: Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation (2004) 110:3149-3155.
39. POMARA G, MORELLI G, POMARA S et al.: Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. J. Androl. (2004) 25:625-629.
40. KLONER RA, MITCHELL M, EMMICK JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am. J. Cardiol. (2003) 92:47M-57M.
41. KLONER RA, JACKSON G, EMMICK JT et al.: Interaction between the phosphodiesterase 5 inhibitor tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. (2004) 172:1935-1940.
42. AUERBACH SM, GITTELMANN M, MAZZU A et al.: Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology (2004) 64:998-1003.
43. AHN HS, CRIM W, PITTS B et al.: Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases: tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv. Second Messenger Phosphoprotein Res. (1992) 25:271-288.
44. CHEN Y, DU R, TRAVERSE JH et al.: Effect of sildenafil on coronary active and reactive hyperemia. Am. J. Physiol. (2000) 279:H2319-H2325.
45. TRAVERSE JH, CHEN YJ, DU R et al.: Cyclic nucleotide phosphodiesterase Type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation (2000) 102:2997-3002.
46. PRZYKLENK K, KLONER RA: Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J. Am. Coll. Cardiol. (2001) 37:286-292.
47. HERRMANN HC, CHANG G, KLUGHERZ B et al.: Hemodynamic effects of Sildenafil in men with severe coronary artery disease. N. Engl. J. Med. (2000) 342:1622-1626.
48. ARRUDA-OLSON AM, MAHONEY DW, NEHRA A et al.: Cardiovascular effects of Sildenafil during exercise in men with known or probable coronary artery disease. JAMA (2002) 287:719-725.
49. THADANI U, SMITH W, NASH S et al.: The effect of vardenafil, a potent and highly selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. (2002) 40:2006-2012.
50. PATTERSON D, MCDONALD TM, EFFRON MB et al.: Tadalafil does not affect rime to ischemia during exercise stress testing in patients with coronary artery disease. Int. J. Impot. Res. (2002):S102 (Abstract).
51. HALCOX JPJ, NOUR KRA, ZALOS G et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol. (2002) 40:1232-1240.
52. BERKELS R, KLOTZ T, STICHT G et al.: Modulation of human platelet aggregation by the phosphodiesterase Type 5 inhibitor sildenafil. J. Cardiovasc. Pharmacol. (2001) 37:413-421.
53. SENZAKI H, SMITH CJ, JUANG GJ et al.: Cardiac phosphodiesterase 5 (cGMp-specific) modulates β-adrenergic signaling in vivo and is downregulated in heart failure. FASEB J. (2001) 15:1718-1726.
54. STIEF CG, ÜCHERT S, BECKER AJ et al.: Effects of Sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology (2000) 55:146-150.
55. SUGIYAMA A, SATOH Y, SHIINA H et al.: Cardiac electrophysiologic and hemodynamic effects of Sildenafil, a PDE5 inhibitor, in anesthetized dogs. J. Cardiovasc. Pharmacol. (2001) 38:940-946.
56. OCKAILI R, SALLOUM F, HAWKINS J et al.: Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. (2002) 283:H263-H269.
57. DAS S, MAULIK N, DAS DK et al.: Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate specific phosphodiesterase 5. Drugs Exp. Clin. Res. (2002) 28:213-219.
58. KLONER RA, REFFELMANN T: Cardiovascular effects of Sildenafil in experimental ischemia-reperfusion (reply to 'Sildenafil-induced cardioprotection in rabbits, by Kukreja, R.C., Ockaili, R., Salloum, F., Xi, L.'). Cardiovasc. Res. (2003) 60:702-703.
59. SWISSA M, OHARA T, LEE MH et al.: Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmia in the swine right ventricle: Am. J. Physiol. (2002) 282:H1787-H1792.
60. GEELEN P, DROLET B, RAIL J et al.: Sildenafil citrate (Viagra) prolongs cardiac repolarisation by blocking the rapid component of the delayed rectifier potassium current. Circulation (2000) 102:275-277.
61. PICCIRILLO G, NOCCO M, LIONETTI M et al.: Effects of Sildenafil citrate (Viagra) on cardiac repolarization and autonomic control in subjects with chronic heart failure. Am. Heart J. (2002) 143:703-710.
62. PHILLIPPS BG, KATO M, PESEK CA et al.: Sympathetic activation by Sildenafil. Circulation (2000) 102:3068-3073.
63. ZHAO L, MASON NA, MORELL NW et al.: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation (2001) 104:424-428.
64. PRASAD S, WILKINSON J, GATZOULIS MA: Sildenafil in primary pulmonary hypertension. N. Engl. J. Med. (2000) 343:1242.
65. LEPORE JJ, MAROO A, PEREIRA NL et al.: Effect of Sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am. J. Cardiol. (2002) 90:677-680.
66. GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Combination therapy with oral Sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. (2002) 136:515-522.
67. GHOFRANI H, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 360:895-900.
68. GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. Eur. Respir. J. (2002) 19:664-671.
69. BOCCHI EA, GUIMARAES G, MOCELIN A et al.: Sildenafil effects on exercise, neurohumoral activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation (2002) 106:1097-1103.
70. WEEKS JL, ZORAGHI R, SEKHAR KR et al.: High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE1 1A4 suggests the absence of PDE1 1A4 cross-reaction in patients. Int. J. Impot. Res. (2004), in press.
71. CORBIN JD BEASLEY A; BLOUNT MA et al.: Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem. Int. (2004) 45:859-863.
72. SHAKIR SAW, WILTON LV, BOSHIER A et al.: Cardiovascular events in users of Sildenafil: results from first phase of prescription event monitoring in England. Br. Med. J. (2001) 322:651-652,
73. MULLER JE: Sexual activity as a trigger for cardiovascular events: what is the risk? Am. J. Cardiol. (1999) 84:2N-5N.
74. DRORY Y, SHAPIRA I, FISMAN EZ et al.: Myocardial ischemia during sexual activity in patients with coronary artery disease. Am. J. Cardiol. (1995) 75:835-837.
75. MULLER JE, MITTLEMAN MA, MACLURE M et al.: Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exercise. JAMA. (1996) 275:1405-1409.
76. MARKOU S, PERIMENIA P, GYFTOPOULOS K et al.: Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int. J. Impot. Res (2004) 16:470-478.
77. KLONER RA, BRINDIS RG, CHEITLIN MD et al.: Roundtable discussion: Tadalafil study group. Am. J. Cardiol. (2003) 92:58M-64M.
78. PADMA-NATHAN H: Sildenafil citrate (Viagra) and erectile dysfunction: a comprehensive of four year update on efficacy, safety, and management options. Urology (2002) 60:I90.
79. HELLSTROM WJG, GITTLEMAN M, KARLIN G et al.: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J. Androl. (2002) 23:763-771.
80. MITTLEMAN MA, GLASSER DB, ORAZEM J: Clinical trials of Sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction a cardiovascular death compared with placebo. Int. J. Clin. Pract. (2003) 57:597-600.
81. CONTI CR, PEPINE CJ, SWEENEY M: Efficacy and safety of Sildenafil citrate in the treatment of ED in patients with ischemic heart disease. Am. J. Cardiol. (1999) 83:29C-34C.
82. JACKSON G, KLONER RA, COSTIGAN TM et al.: Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J. Sex. Med. (2004) 1:161-167.
83. BOHLEN JG, HELD JP, SANDERSON MO et al.: Heart rare and blood pressure response to four sexual activities. Arch. Int. Med. (1984) 144:1745-1748.
84. LARSON JL, MCNAUGHTON MW, KENNEDY JW et al.: Heart rate and blood pressure response to sexual activity and a stair climbing test. Heart Lung (1980) 9:1025-1030.
85. UENO M: The so-called coition death. Jpn. J. Leg. Med. (1963) 17:330-335.
86. MUIRHEAD GJ, WILNER K, COLBURN W et al.: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br. J. Clin. Pharmacol. (2002) 53:21S-30S.
87. FAGAN TC, BUTTLER S, MARBURY T et al.: Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am. J. Cardiol. (2001) 88:760-766.